A pharmaceutical company has $400M (2026 USD) to allocate across twelve drug programs. Each program has an estimated NPV, a development cost, and shared resource demands (clinical-trial slots, regulatory bandwidth). You can fund a program or not — there is no half-trial. Maximize total NPV subject to budget and resource caps. That is a 0-1 integer program, and it is the bread and butter of strategic-finance teams at Pfizer, Boeing, and every utility deciding which transmission lines to build. Solvers like Gurobi will dispatch a twelve-binary problem in milliseconds and a thousand-binary capital plan in minutes — but the modeling effort is where consultancies bill the hours.
06
Capital budgeting
Every CFO who has ever picked which projects to fund has solved a 0-1 IP, with or without knowing it.